Enhertu showed improved iDFS over Kadcyla in early-stage HER2-positive breast cancer with residual disease post-neoadjuvant ...

Adding pirfenidone to mycophenolate mofetil shows no significant improvement in lung function compared with mycophenolate ...

Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 -- Affecting up to 100,000 people in the U.S. and up to 5.6 ...

The novel radiotracer ¹⁸F-FAPI-RGD in PET/CT scans shows potential for diagnosing ILD in connective tissue disease patients by highlighting fibroblast activation and tissue remodeling. Patients with ...

The FDA today approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of progressive pulmonary fibrosis (PPF ...

Here are the top 5 most-read pulmonary fibrosis articles of 2025.

Individuals with interstitial lung disease (ILD) had more than a 13-fold higher incidence rate of lung cancer than those without ILD. The association persisted after adjustment for confounders, was ...

Serac Healthcare, a clinical radiopharmaceutical company, and the University of Exeter have announced the commencement of a Phase II study involving a novel molecular SPECT imaging agent, ...

Have you heard of Interstitial Lung Disease (ILD)? Like most people, you may not have – ILDs are, after all, a group of lung disorders that are significantly rare compared to other pulmonary diseases.

Please provide your email address to receive an email when new articles are posted on . Eight clusters of related biomarkers were significantly associated with RA-ILD. The biomarkers led to a greater ...

The FDA approved nerandomilast tablets for adults with progressive pulmonary fibrosis, according to an industry press release ...